Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of CNTO 1275 in the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis.
Brief Summary: The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.


Options:
A: Arm Label: Abatacept (30/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (10/10); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Abatacept (3/3); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept (10/10), Abatacept (3/3), Abatacept (30/10) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Group I; Type: EXPERIMENTAL; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group II; Type: PLACEBO_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Placebo for adalimumab | Arm Label: Group III; Type: ACTIVE_COMPARATOR; Interventions: Drug: Guselkumab 100 mg, Drug: Placebo for guselkumab, Drug: Adalimumab | Intervention Type: DRUG; Name: Guselkumab 100 mg; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Placebo for guselkumab; Assigned to Arm(s): Group I, Group II, Group III | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Group III | Intervention Type: DRUG; Name: Placebo for adalimumab; Assigned to Arm(s): Group I, Group II
C: Arm Label: Group I: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg | Arm Label: Group II: Ustekinumab 45 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 45 mg | Arm Label: Group III: Ustekinumab 90 mg; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab (CNTO 1275) 90 mg | Intervention Type: DRUG; Name: Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg; Assigned to Arm(s): Group I: Placebo | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 45 mg; Assigned to Arm(s): Group II: Ustekinumab 45 mg | Intervention Type: DRUG; Name: Ustekinumab (CNTO 1275) 90 mg; Assigned to Arm(s): Group III: Ustekinumab 90 mg
D: Arm Label: UCB4940 8 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 40 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 160 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 480 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: UCB4940 640 mg; Type: EXPERIMENTAL; Interventions: Drug: UCB4940 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: UCB4940; Assigned to Arm(s): UCB4940 160 mg, UCB4940 40 mg, UCB4940 480 mg, UCB4940 640 mg, UCB4940 8 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C